Clinical Trial Update: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Phase 3]

View source ↗

Summary

Phase 3 trial of inhaled molgramostim for autoimmune pulmonary alveolar proteinosis has posted results and the study remains active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Pulmonary Alveolar Proteinosis

Drugs mentioned

• Molgramostim (granulocyte-macrophage colony-stimulating factor (GM-CSF))

Snippet

Sponsor: Savara Inc. | Conditions: Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-07